The transcriptomic profiles of the constituent monotherapies of synergistic drug pairs tend to be correlated and result in novel gene expression in the combinations.

Combined EGFR and SOS1 inhibition synergize to inhibit NSCLC spheroid growth.

Data-driven systems biology models of signaling predict cellular response to untested perturbations and can nominate drug combinations to overcome drug resistance in cancer cells.

Combining pre-erythrocytic and transmission blocking antibodies enhances the overall control and potential elimination of malaria within both mosquito and vertebrate populations.

High-performance computing simulations reveal how two remote sites in the multidrug transporter AcrB work together for drug extrusion using the proton-motive force.

A mathematical model of osteoporosis explains why the sequence of osteoporosis medications matters for short-term and long-term treatment success.

The manner in which protons control the conformational behaviour of mammalian peptide transporters is revealed through state-of-the-art molecular dynamics simulations supported by cell-based assays.

Identification and exploitation of interactions between the antifungal drug fluconazole and FDA- approved drugs has the potential to improve treatment for patients with difficult-to-treat systemic fungal infections.

Drugs in a curative chemotherapy regimen are independently effective and resisted by different mechanisms, so cancer cells have little chance of surviving all drugs, and this benefit occurs without synergistic interactions.